Ocular Therapeutix initiates first pivotal trial of OTX-TKI for wet AMD

OCULAR THERAPEUTIX, INC

Activated first US clinical trial site; expects to enroll first subject by year-end 2023.
Superiority trial of ~300 evaluable treatment-naïve wet AMD subjects randomized to aflibercept or OTX-TKI implant.
Filed Special Protocol Assessment request with FDA for trial design; enrollment will wait for SPA feedback.
OTX-TKI is an axitinib intravitreal implant, a potential long-acting therapy for wet AMD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.